|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales: | |||||
| Cost of product (excluding amortization) | |||||
| Amortization of patented formulations | |||||
| Total cost of sales | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general, and administrative | |||||
| Amortization of other intangible assets | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Interest expense | |||||
| Interest income | |||||
| Other (income) expense, net: | |||||
| Loss on extinguishment of debt | |||||
| Tax Receivable Agreement liability adjustment | |||||
| Other (income) expense, net | |||||
| Total other (income) expense, net | |||||
| (Loss) income before provision for income taxes | |||||
| Income tax provision | |||||
| Net (loss) income | |||||
| Net (loss) income per share: | |||||
| Net (loss) income per share: Basic (in usd per share) | |||||
| Net (loss) income per share: Diluted (in usd per share) | |||||
| Weighted average common shares outstanding: | |||||
| Weighted average common shares outstanding: Basic (in shares) | |||||
| Weighted average common shares outstanding: Diluted (in shares) | |||||
| Other comprehensive income (loss): | |||||
| Unrealized gain (loss) on derivatives, net of income tax effect | |||||
| Total other comprehensive income (loss) | |||||
| Comprehensive (loss) income | |||||
Loading...